Benjamin Hohl Sells 814 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 814 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $24,420.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.27, for a total value of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total value of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total value of $140,070.00.

Enliven Therapeutics Stock Performance

Shares of ELVN opened at $28.98 on Friday. The company has a 50-day simple moving average of $24.62 and a 200-day simple moving average of $22.93. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $30.03. The firm has a market capitalization of $1.36 billion, a P/E ratio of -15.02 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17. As a group, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors have recently bought and sold shares of the business. Quest Partners LLC raised its stake in shares of Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after buying an additional 742 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics in the first quarter worth about $167,000. SG Americas Securities LLC bought a new position in Enliven Therapeutics during the third quarter worth about $256,000. The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics during the second quarter valued at approximately $322,000. Finally, Blackstone Inc. acquired a new stake in Enliven Therapeutics during the first quarter valued at approximately $443,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.